# OnCo record paper-neosphere-lancet-oncol-2012 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-neosphere-lancet-oncol-2012/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-neosphere-lancet-oncol-2012" ;
  schema:name "Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial"@en ;
  schema:description "Published report from the NeoSphere trial registered as NCT00545688, in The Lancet Oncology (2012), chosen as the most cited paper whose own text cites the registry id."@en ;
  schema:url <https://onco.cc/key-papers/paper-neosphere-lancet-oncol-2012/> ;
  schema:dateModified "2026-09-22"^^xsd:date ;
  schema:citation <https://doi.org/10.1016/s1470-2045(11)70336-9>, <https://pubmed.ncbi.nlm.nih.gov/22153890/>, <https://europepmc.org/article/MED/22153890>, <https://clinicaltrials.gov/study/NCT00545688> ;
  onco:tag "europepmc-ingest" ;
  schema:sameAs <https://doi.org/10.1016/s1470-2045(11)70336-9> ;
  schema:datePublished "2012"^^xsd:gYear ;
  schema:author "Gianni L, Pienkowski T, Im YH, et al." ;
  onco:trials <https://onco.cc/trials/neosphere/> ;
  onco:journals <https://onco.cc/journals/lancet-oncology/> .